Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans.
Vicencio JM, Evans R, Green R, An Z, Deng J, Treacy C, Mustapha R, Monypenny J, Costoya C, Lawler K, Ng K, De-Souza K, Coban O, Gomez V, Clancy J, Chen SH, Chalk A, Wong F, Gordon P, Savage C, Gomes C, Pan T, Alfano G, Dolcetti L, Chan JNE, Flores-Borja F, Barber PR, Weitsman G, Sosnowska D, Capone E, Iacobelli S, Hochhauser D, Hartley JA, Parsons M, Arnold JN, Ameer-Beg S, Quezada SA, Yarden Y, Sala G, Ng T.
Vicencio JM, et al. Among authors: monypenny j.
Cell Death Dis. 2022 Mar 28;13(3):274. doi: 10.1038/s41419-022-04701-3.
Cell Death Dis. 2022.
PMID: 35347108
Free PMC article.